Friday, February 23, 2018
|7:00 am ||Registration & Breakfast|
|7:35 am ||Welcome
Nassir Marrouche, MD
Kevin Campbell, MD; John Mandrola, MD
Chairs: Melvin Scheinman, MD; Fred Han, MD
|7:45 am||Is AF ablation safer than AAD? A systematic review
John P. DiMarco, MD, PhD
|8:00 am||Interaction between hypercoagulability and atrial fibrillation
Ulrich Schotten, MD, PhD
|8:15 am||Clinical outcomes of AF mapping and rotor guided ablation
David Wilber, MD
|8:30 am||LAA closure: Long-term follow-up data
Rahul N. Doshi, MD
Chairs: David Wilber, MD; Roger Freedman, MD
|9:00 am||It is all about lesion delivery: Is electroporation the future of AF ablation?
Pierre Jais, MD
|9:15 am||Atrial MR imaging: How to improve resolution?
Dana C. Peters, PhD
|9:30 am||LAA closure devices: Benefit beyond stroke prevention?
Dhanunjaya Lakkireddy, MD
|9:45 am||Is AF a marker or a risk for stroke?
Nazem Akoum, MD, MS
Chairs: Jonathan Piccini, MD; Melvin Scheinman, MD
|10:30 am||Is AF ablation a first-line therapy in 2018?
Eric Prystowsky, MD
|10:45 am||CABANA: What to expect?
Douglas Packer, MD
|11:00 am||Esophageal protection during AF ablation
Moussa C. Mansour, MD
|11:15 am||QoL post AF ablation: the CAPTAF trial
Carina Blomström-Lundqvist, MD, PhD
Chairs: Michael Cutler, DO, PhD; Fred Han, MD
|12:30 pm||Cryo-balloon for AF: Long-term results
Bradley Knight, MD
|12:45 pm||Is it AF or the myopathy? Lessons from MR imaging
Saman Nazarian, MD, PhD
|1:00 pm||Atrial fibrosis modeling: Clinical implications
Natalia Trayanova, PhD
|1:15 pm||Mortality benefit post AF ablation: The CASTLE-AF trial
Johannes Brachmann, MD
Chairs: Jonathan Piccini, MD; Roger Freedman, MD
|1:45 pm||Do we still need to monitor for asymptomatic AF after ablation?
Suneet Mittal, MD
|2:00 pm||Rotational activity and atrial fibrosis: How DECAAF II might help?
Christian Sohns, MD
|2:15 pm||Post-ablation blanking period: 4, 8, 12 or zero weeks?
David Callans, MD
|2:30 pm||Fibrosis and clinical AF: What are the DECAAFs teaching us?
Nassir Marrouche, MD
Chairs: David Callans, MD; Gaston R. Vergara, MD
|3:15 pm||Targeting rotational activity during re-do procedures
Sanjiv M. Narayan, MD, PhD
|3:30 pm||Catheterized fiber-optics confocal microscopy for mapping of atrial fibrosis
Frank B. Sachse, PhD
|3:45 pm||Treatment of esophageal injury post AF ablation: A GI perspective
Deborah Fisher, MD, MHS
|4:00 pm||AF in heart failure patients: Lessons from SCD-HeFT
Jeanne Poole, MD
Moderators: Frank B. Sachse, PhD; Suneet Mittal, MD
|4:30 pm||Atrial fibrosis in an experimental model: What have we learned?
Stanley Nattel, MD
|4:45 pm||When to anticoagulate AF patients with CHA2DS2-VASc <2?
Andrea M. Russo, MD
|5:00 pm||Risk factors for AF in women
Christine Albert, MD, MPH
Moderators: Walid Saliba, MD; Darryl S. Wells, MD
|5:35 pm||Roundtable: How, when and why to monitor for AF—Examples from practice
Ahmad Abdul-Karim, MD; Andres Bochoeyer, MD; Marcos Daccarett, MD; Bengt
Herweg, MD; Nischala Nannapaneni,
MD; Leenhapong Navaravong, MD; Kamran Rizvi, MD; Bassam Wanna, MD
Saturday, February 24, 2018
|7:00 am ||Registration & Breakfast
Chairs: John Mandrola, MD; Alexies Ramirez, MD
|7:30 am||Real world impact of NOACs: Neurologist perspective
Scott Brehaut, MD
|7:45 am||Debate: DOACs should be given for at least 6 months post-LAA implant
Pro: Jonathan Lowy, MD
Con: Julian Chun, MD
|8:00 am||ESC AF guidelines update
Gerhard Hindricks, MD, PhD
|8:15 am||How much AF is too much? (Especially with wearables everywhere…)
Mintu Turakhia, MD
Chairs: Alexandru Costea, MD; Fred Han, MD
|8:45 am||Contemporary real-world and registry data of NOACs: Is Coumadin Dead?
Jonathan Hsu, MD, MAS
|9:00 am||Low-voltage zone vs MR detected fibrosis: A comparison
Takanorai Yamaguchi, MD
|9:15 am||Why are we struggling to agree on an ideal mapping system for AF?
Olaf Döessel, PhD
|9:30 am||Ablation of AF: 10 years of follow-up
Andrea Natale, MD
Chairs: Prash Sanders, MBBS, PhD; Thomas J. McGarry, MD, PhD
|10:15 am||AF & OSA: Chicken and the egg
Thomas F. Deering, MD, MBA
|10:30 am||Cardiac fibrosis and treatment outcome: Lessons from CAMERA-MRI
Jonathan M. Kalman, MBBS, PhD
|10:45 am||A Novel AF risk scoring model using MRI
Brent D. Wilson, MD, PhD
|11:00 am||Ablation lesions post ablation: What have we learned from imaging?
Mihail G. Chelu, MD, PhD
Chairs: Thomas Deneke, MD; Nathan Segerson, MD
|12:30 pm||Approaches to ablate persistent AF in 2018: Why too many?
Gregory Michaud, MD
|12:45 pm||How to modify lifestyle and educate the AF patient?
Prash Sanders, MBBS, PhD
|1:00 pm||Role of atrial fibrosis during surgical AF ablation
Ralph J. Damiano, Jr., MD
|1:15 pm||How to best monitor treatment with NOACs?
Elaine M. Hylek, MD, MPH
Chairs: Atul Verma, MD; Stephen Rechenmacher, MD
|1:45 pm||Real-time MRI cryo-balloon guided ablation
Evgueni G. Kholmovski, PhD
|2:00 pm||Radiofrequency balloon systems
Amin Al-Ahmad, MD
|2:15 pm||Real-time MRI for cardiac ablation
Philipp Sommer, MD
|2:30 pm||Is transmural lesion an important endpoint during AF ablation? Show me the data!
David Haines, MD
Chairs: Christian Mahnkopf, MD; Alexandru Costea, MD
|3:15 pm||Patient-reported outcomes in AF
Benjamin A. Steinberg, MD, MHS
|3:30 pm||Off-label treatment of AF
Kimberly A. Selzman, MD, MPH
|3:45 pm||Importance of durable PVI for persistent AF
Atul Verma, MD
Chairs: Nassir Marrouche, MD; David Haines, MD
|4:15 pm||Treatment of AF: Heart failure specialist’s perspective
Heribert Schunkert, MD
|4:30 pm||4D flow in AF detected using MRI
Christopher J. McGann, MD
|4:45 pm||How early should we ablate AF? Temporal and structural criteria
Oussama Wazni, MD
Chairs: Kevin Campbell, MD; John Mandrola, MD
John D. Day, MD; Christian Mahnkopf, MD; Debbe McCall, MBA; Claudio Molito; Mellanie True Hills; Gaston R. Vergara, MD
*Agenda is subject to change